These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents. Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218 [TBL] [Abstract][Full Text] [Related]
26. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors. Kortenhorst MS; Wissing MD; Rodríguez R; Kachhap SK; Jans JJ; Van der Groep P; Verheul HM; Gupta A; Aiyetan PO; van der Wall E; Carducci MA; Van Diest PJ; Marchionni L Epigenetics; 2013 Sep; 8(9):907-20. PubMed ID: 23880963 [TBL] [Abstract][Full Text] [Related]
27. BCL11B-Mediated Epigenetic Repression Is a Crucial Target for Histone Deacetylase Inhibitors in Cutaneous T-Cell Lymphoma. Fu W; Yi S; Qiu L; Sun J; Tu P; Wang Y J Invest Dermatol; 2017 Jul; 137(7):1523-1532. PubMed ID: 28288848 [TBL] [Abstract][Full Text] [Related]
28. Embelin inhibits viability of cutaneous T cell lymphoma cell lines HuT78 and H9 by targeting inhibitors of apoptosis. Abdulrahman N; Leo R; Boumenar HA; Ahmad F; Mateo JM; Jochebeth A; Al-Sowaidi NK; Sher G; Ansari AW; Alam M; Uddin S; Ahmad A; Steinhoff M; Buddenkotte J Leuk Lymphoma; 2023 Dec; 64(14):2236-2248. PubMed ID: 37708450 [TBL] [Abstract][Full Text] [Related]
29. The Robust Tumoricidal Effects of Combined BET/HDAC Inhibition in Cutaneous T-Cell Lymphoma Can Be Reproduced by ΔNp73 Depletion. Zhao L; Hsiao T; Stonesifer C; Daniels J; Garcia-Saleem TJ; Choi J; Geskin L; Rook AH; Wood GS J Invest Dermatol; 2022 Dec; 142(12):3253-3261.e4. PubMed ID: 35787399 [TBL] [Abstract][Full Text] [Related]
30. Combined inhibition of Bcl-2 and NFκB synergistically induces cell death in cutaneous T-cell lymphoma. Froehlich TC; Müller-Decker K; Braun JD; Albrecht T; Schroeder A; Gülow K; Goerdt S; Krammer PH; Nicolay JP Blood; 2019 Aug; 134(5):445-455. PubMed ID: 31167801 [TBL] [Abstract][Full Text] [Related]
31. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL. Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520 [TBL] [Abstract][Full Text] [Related]
32. Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma. Andrews JM; Schmidt JA; Carson KR; Musiek AC; Mehta-Shah N; Payton JE EBioMedicine; 2019 Aug; 46():170-183. PubMed ID: 31358475 [TBL] [Abstract][Full Text] [Related]
33. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Fantin VR; Loboda A; Paweletz CP; Hendrickson RC; Pierce JW; Roth JA; Li L; Gooden F; Korenchuk S; Hou XS; Harrington EA; Randolph S; Reilly JF; Ware CM; Kadin ME; Frankel SR; Richon VM Cancer Res; 2008 May; 68(10):3785-94. PubMed ID: 18483262 [TBL] [Abstract][Full Text] [Related]
34. Nrf2 Expression and Apoptosis in Quercetin-treated Malignant Mesothelioma Cells. Lee YJ; Lee DM; Lee SH Mol Cells; 2015 May; 38(5):416-25. PubMed ID: 25896339 [TBL] [Abstract][Full Text] [Related]
35. Silencing of Hsp27 and Hsp72 in glioma cells as a tool for programmed cell death induction upon temozolomide and quercetin treatment. Jakubowicz-Gil J; Langner E; Bądziul D; Wertel I; Rzeski W Toxicol Appl Pharmacol; 2013 Dec; 273(3):580-9. PubMed ID: 24126416 [TBL] [Abstract][Full Text] [Related]
36. MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor. Chakraborty AR; Robey RW; Luchenko VL; Zhan Z; Piekarz RL; Gillet JP; Kossenkov AV; Wilkerson J; Showe LC; Gottesman MM; Collie NL; Bates SE Blood; 2013 May; 121(20):4115-25. PubMed ID: 23532732 [TBL] [Abstract][Full Text] [Related]
37. Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. Kavanaugh SM; White LA; Kolesar JM Am J Health Syst Pharm; 2010 May; 67(10):793-7. PubMed ID: 20479100 [TBL] [Abstract][Full Text] [Related]
38. Chemotherapeutic treatment is associated with Notch1 induction in cutaneous T-cell lymphoma. Kamstrup MR; Biskup E; Manfè V; Savorani C; Liszewski W; Wirèn J; Specht L; Gniadecki R Leuk Lymphoma; 2017 Jan; 58(1):171-178. PubMed ID: 27181628 [TBL] [Abstract][Full Text] [Related]
39. Differential Response of Mycosis Fungoides Cells to Vorinostat. Bordeaux ZA; Reddy SV; Lee K; Lu W; Choi J; Miller M; Roberts C; Pollizzi A; Kwatra SG; Kwatra MM Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175780 [TBL] [Abstract][Full Text] [Related]
40. Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma. Xu J; Huang H; Wang S; Chen Y; Yin X; Zhang X; Zhang Y Arch Dermatol Res; 2020 Sep; 312(7):513-525. PubMed ID: 31676945 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]